Drug intelligence / Profile preview

SO-006D

Development stage: Preclinical
Lead developer: SOICUM
Modality: Small Molecules

Overview

SO-006D is a preclinical-stage small molecule drug candidate being developed by SOCIUM for the treatment of pancreatic cancer. Identified as a new compound derivative, it is designed to improve therapeutic efficacy in pancreatic oncology. As of mid-2026, the specific biological target and molecular mechanism of action remain undisclosed by the developer.

Beyond the preview

Go deeper on SO-006D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SO-006D.

Explore the full profile